Remdesivir, on the road to DisCoVeRy

doi:10.1016/S1473-3099(21)00559-4

Comment

. 2022 Feb;22(2):153-155.

doi: 10.1016/S1473-3099(21)00559-4. Epub 2021 Sep 14.

Remdesivir, on the road to DisCoVeRy

Iwein Gyselinck¹, Wim Janssens²

Affiliations

¹ Respiratory Diseases, University Hospitals Leuven, BREATHE Research Group, Department CHROMETA, KU Leuven, 3000 Leuven, Belgium. Electronic address: iwein.gyselinck@kuleuven.be.
² Respiratory Diseases, University Hospitals Leuven, BREATHE Research Group, Department CHROMETA, KU Leuven, 3000 Leuven, Belgium.

PMID: 34534513
PMCID: PMC8439616
DOI: 10.1016/S1473-3099(21)00559-4

Comment

Remdesivir, on the road to DisCoVeRy

Iwein Gyselinck et al. Lancet Infect Dis. 2022 Feb.

. 2022 Feb;22(2):153-155.

doi: 10.1016/S1473-3099(21)00559-4. Epub 2021 Sep 14.

Authors

Iwein Gyselinck¹, Wim Janssens²

Affiliations

¹ Respiratory Diseases, University Hospitals Leuven, BREATHE Research Group, Department CHROMETA, KU Leuven, 3000 Leuven, Belgium. Electronic address: iwein.gyselinck@kuleuven.be.
² Respiratory Diseases, University Hospitals Leuven, BREATHE Research Group, Department CHROMETA, KU Leuven, 3000 Leuven, Belgium.

PMID: 34534513
PMCID: PMC8439616
DOI: 10.1016/S1473-3099(21)00559-4

No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment in

Clindamycin-resistant Streptococcus pyogenes in Chinese children.
Yu D, Liang Y, Zheng Y, Yang Y. Yu D, et al. Lancet Infect Dis. 2021 Dec;21(12):1631-1632. doi: 10.1016/S1473-3099(21)00699-X. Lancet Infect Dis. 2021. PMID: 34838224 Free PMC article. No abstract available.

Comment on

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Lê MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F; DisCoVeRy Study Group. Ader F, et al. Lancet Infect Dis. 2022 Feb;22(2):209-221. doi: 10.1016/S1473-3099(21)00485-0. Epub 2021 Sep 14. Lancet Infect Dis. 2022. PMID: 34534511 Free PMC article. Clinical Trial.

Cited by

Assessing the evidence on remdesivir.
Trøseid M, Hites M, Barratt-Due A, Ader F, Yazdanpanah Y. Trøseid M, et al. Lancet Infect Dis. 2021 Dec;21(12):1630-1631. doi: 10.1016/S1473-3099(21)00695-2. Lancet Infect Dis. 2021. PMID: 34838222 Free PMC article. No abstract available.
Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study.
Spagnuolo V, Voarino M, Tonelli M, Galli L, Poli A, Bruzzesi E, Racca S, Clementi N, Oltolini C, Tresoldi M, Rovere Querini P, Dagna L, Zangrillo A, Ciceri F, Clementi M, Castagna A; COVID-BioB Study Group. Spagnuolo V, et al. Drug Des Devel Ther. 2022 Oct 19;16:3645-3654. doi: 10.2147/DDDT.S369473. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 36268521 Free PMC article.
Efficacy and Safety of a Phytopharmaceutical Drug Derived from Cocculus hirsutus in Adults with Moderate COVID-19: a Phase 2, Open-label, Multicenter, Randomized Controlled Trial.
Joglekar S, Iyer SS, Parate R, Khobragade AA, Patil R, Bhushan S, Halnor DM, Rajadhyaksha GC, Parmar K, Dhawan S, Mehta S, Joshi SR. Joglekar S, et al. Infect Dis Ther. 2022 Apr;11(2):807-826. doi: 10.1007/s40121-022-00604-0. Epub 2022 Feb 18. Infect Dis Ther. 2022. PMID: 35179709 Free PMC article.
Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials.
Dijk SW, Krijkamp EM, Kunst N, Gross CP, Wong JB, Hunink MGM. Dijk SW, et al. Value Health. 2022 Aug;25(8):1268-1280. doi: 10.1016/j.jval.2022.03.016. Epub 2022 Apr 28. Value Health. 2022. PMID: 35490085 Free PMC article.

References

1. Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00485-0. published online Sept 14. - DOI - PMC - PubMed
1. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324:1048–1057. - PMC - PubMed
1. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19—final report. N Engl J Med. 2020;383:1813–1826. - PMC - PubMed
1. Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for COVID-19—interim WHO Solidarity trial results. N Engl J Med. 2021;384:497–511. - PMC - PubMed
1. Paules CI, Gallagher SK, Rapaka RR, et al. Remdesivir for the prevention of invasive mechanical ventilation or death in COVID-19—a post-hoc analysis of the adaptive COVID-19 treatment trial-1 cohort data. Clin Infect Dis. 2021 doi: 10.1093/cid/ciab695. published online Aug 11. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00485-0. published online Sept 14. - DOI - PMC - PubMed

[2] Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00485-0. published online Sept 14. - DOI - PMC - PubMed

[3] Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324:1048–1057. - PMC - PubMed

[4] Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324:1048–1057. - PMC - PubMed

[5] Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19—final report. N Engl J Med. 2020;383:1813–1826. - PMC - PubMed

[6] Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19—final report. N Engl J Med. 2020;383:1813–1826. - PMC - PubMed

[7] Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for COVID-19—interim WHO Solidarity trial results. N Engl J Med. 2021;384:497–511. - PMC - PubMed

[8] Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for COVID-19—interim WHO Solidarity trial results. N Engl J Med. 2021;384:497–511. - PMC - PubMed

[9] Paules CI, Gallagher SK, Rapaka RR, et al. Remdesivir for the prevention of invasive mechanical ventilation or death in COVID-19—a post-hoc analysis of the adaptive COVID-19 treatment trial-1 cohort data. Clin Infect Dis. 2021 doi: 10.1093/cid/ciab695. published online Aug 11. - DOI - PMC - PubMed

[10] Paules CI, Gallagher SK, Rapaka RR, et al. Remdesivir for the prevention of invasive mechanical ventilation or death in COVID-19—a post-hoc analysis of the adaptive COVID-19 treatment trial-1 cohort data. Clin Infect Dis. 2021 doi: 10.1093/cid/ciab695. published online Aug 11. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Remdesivir, on the road to DisCoVeRy

Affiliations

Remdesivir, on the road to DisCoVeRy

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Conflict of interest statement

Comment in

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources